The role of MRI in clinical trials of multiple sclerosis: Comparison of image processing techniques

Annals of Neurology

Volumn 41, Issue 1, 1997, Pages 125-132

  Evans, A C ^a,c   Frank, J A ^b   Antel, J ^c   Miller, D H ^d  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; AUTOANALYSIS; CLINICAL TRIAL; DATA BASE; DEMYELINATING DISEASE; HUMAN; IMAGE PROCESSING; INTERMETHOD COMPARISON; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 0031033842     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410123     Document Type: Article

References (14)

1. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
2. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990;40:971-975
3. Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol 1994;36:S80-S85
4. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II-MRI analysis results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
5. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
6. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
7. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
8. Gass A, Barker GJ, Kidd D, et al. Gorrelation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62-67
9. I-weighted) spin-echo images. Neurology 1995;45:1684-1690
10. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
11. Filippi M, Horsfield MA, Campi A, et al. Resolution-dependent estimates of lesion volume in magnetic resonance imaging studies of the brain in multiple sclerosis. Ann Neurol 1995;38:749-754
12. Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain: 3-dimensional proportional system: an approach to cerebral imaging. New York: Georg Thieme, 1988
13. Evans AC, Marrett S, Neelin P, et al. Anatomical mapping of functional activation in stereotaxic coordinate space. Neuroimage 1992;1:43-63
14. Kamber M, Shinghal R, Collins DL, et al. Model-based 3D segmentation of multiple sclerosis lesions in magnetic resonance brain images. IEEE Trans Med Imag 1995;14:442-453